TargetBeta
CYP11B2
cytochrome P450 family 11 subfamily B member 2 · also CYP11BL, CPN2, P-450C18, P450aldo · Cytochrome P450 family 11
2 programs in company-led studies act on CYP11B2, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Osilodrostatrule | Novartis | phase 4 | 132 running | CYP11B1 | NCIt |
| vicadrostat | Boehringer Ingelheim | phase 3 | 165 running | SLC5A2 | the company's pipeline |
Conditions their studies are in
- Adrenocortical Hyperfunction, 1 program
- Cushing Syndrome, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Diabetic Nephropathies, 1 program
- Essential Hypertension, 1 program
- Heart Failure, 1 program
- Hypertension, 1 program
- Liver Diseases, 1 program
- Pituitary ACTH Hypersecretion, 1 program
- Renal Insufficiency, Chronic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 11, 2026vicadrostat · Boehringer Ingelheim · phase 3 · NCT07845630
- Jul 21, 2027Osilodrostat · Novartis · phase 4 · NCT03708900
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.